Dr. Lal PathLabs Ltd (NSE:LALPATHLAB) is set to release its Q2 2026 earnings on Oct 31, 2025. The consensus estimate for Q2 2026 revenue is $7.38 billion, and the earnings are expected to come in at ...

The balance sheet gives him room to move - Lal PathLabs is sitting on about Rs.1,400 crore of net cash and no debt, and can blend cash with equity, if a compelling platform emerges, Goel said.

When my father, Dr SK Lal, decided to make India his country at the time of Partition, and came to Delhi from Rawalpindi, he had 31 dependents with him," recalls (Hony) Brigadier Dr Arvind Lal, ...

Dr Lal PathLabs Q3 results date: Diagnostics company Dr Lal PathLabs is slated to meet next to consider and approve its financial results for the quarter ended December 30, 2024 (Q3), the company ...

Dr Lal PathLabs Q4 Results: Revenue from operations in the fourth quarter of FY24 rose 11 per cent to ₹545.5 crore India's biggest diagnostics firm by revenue's posted a bigger profit for the fourth ...

After a three-year strategic pause, diagnostics firm is unlocking its balance-sheet capacity look for growth-boosting acquisitions ...

Proteomics enables the observation of direct cellular function to gain insights on protein-driven disease traits. (Image Credits: Pixabay) Dr. Lal Pathlabs on Tuesday announced that it has ...

Dr Lal PathLabs shares have seen a correction of around 14 percent so far in 2024, particularly severe compared to listed peers, according to Kotak Institutional Equities. Shares of Dr Lal PathLabs ...

Dr Lal PathLabs reported a 29% increase in consolidated profit after tax, reaching Rs 108 crore for Q1 FY2024, up from Rs 84 crore last year. Revenue also grew to Rs 602 crore. The board approved an ...